Seer Inc.
SEER | NASDAQ
$1.87
+$0.01 (+0.54%)
Sep 22, 2026, 1:25 PM ET · Market open
Company Profile
Seer, Inc. is a life sciences firm specializing in developing and commercializing advanced technologies designed to unravel the complexities of the proteome. At the core of its offerings is the Proteograph Product Suite, an integrated platform comprising specialized consumables, automated instrumentation, and sophisticated software. This comprehensive solution empowers researchers to conduct advanced proteomic studies across various applications, including therapeutic and diagnostic investigations, as well as clinical trials. The company markets its products exclusively for research applications, serving academic institutions, diverse life sciences and research laboratories, and biopharmaceutical and biotechnology enterprises. Notably, these offerings are intended for non-diagnostic and non-clinical purposes. Seer has established collaborative agreements with entities such as Discovery Life Sciences, LLC, and the Salk Institute for Biological Studies. Originally incorporated in 2017 as Seer Biosciences, Inc., the company adopted its current name, Seer, Inc., in July 2018. Its headquarters are situated in Redwood City, California.
Key Executives
| Name | Position |
|---|---|
| Omid C. Farokhzad | Founder, Chief Executive Officer, & Chair of the Board of Directors |
| David R. Horn | President,Treasurer & Chief Financial Officer |
| Marissa Dixon | Chief People Officer |
| Anthony Bazarko | Chief Commercial Officer |
| Asim Siddiqui | Senior Vice President of Research & Tech Development |
| Kenny Ross | Chief Operations & Product Officer |
| Martin Goldberg | Senior Vice President of Product Development |
| Serafim Batzoglou | Chief Data Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 19, 2026 | 4 | Filing |
| Aug 11, 2026 | 10-Q | Quarterly Report |
| Aug 11, 2026 | 8-K | Current Report |
| Jul 31, 2026 | 8-K | Current Report |
| Jul 31, 2026 | 8-K | Current Report |
| Jul 30, 2026 | 4 | Filing |
| Jul 30, 2026 | 4 | Filing |
| Jul 30, 2026 | 4 | Filing |
| Jul 30, 2026 | 4 | Filing |
| Jul 30, 2026 | 4 | Filing |
Seer Inc.
| Country | United States |
| IPO Date | Dec 3, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 124 |
| CEO | Omid C. Farokhzad |
Contact Details
3800 Bridge Parkway Redwood City,
California 94065 United States
Stock Details
| Ticker Symbol | SEER |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001726445 |
| CUSIP Number | 81578P106 |
| ISIN Number | US81578P1066 |
| SIC Code | 3826 |
Add to Watchlist
Select watchlists to add or remove SEER